• Cyclophilin A’s Essential Role in Cyclosporin A Immunosuppre

  2026-07-08

  This study demonstrates that cyclophilin A (CypA) is indispensable for cyclosporin A (CsA)-mediated immunosuppression, as mice lacking CypA are resistant to CsA’s effects on T-cell activation. These findings clarify the molecular specificity of CsA action and have practical implications for immunosuppression assays and transplant research.

• EZH2 Inhibitors in HPV-Driven Cervical Cancer: Mechanistic I

  2026-07-08

  This study demonstrates that selective EZH2 inhibitors, particularly EPZ-6438, induce apoptosis and cell cycle arrest in both HPV-positive and HPV-negative cervical cancer cells. By elucidating key epigenetic mechanisms and comparing efficacy to cisplatin, the findings highlight new avenues for targeted therapy in HPV-associated malignancies.

• Anti-HMGB1 Rabbit Monoclonal Antibody: Practical Workflow Gu

  2026-07-07

  The Anti-HMGB1 Rabbit Monoclonal Antibody (SKU MA3057) enables targeted detection of HMGB1 protein in human, mouse, and rat samples across Western blot, immunohistochemistry, and flow cytometry workflows. It is designed to deliver high specificity in chromatin protein detection for research purposes but should not be used in diagnostic or therapeutic settings.

• Imipramine in Translational Research: Lipidomics, Autophagy

  2026-07-07

  This article explores Imipramine's mechanistic role as a tricyclic antidepressant in modulating autophagy and apoptosis, bridging insights from lipidomics and viral-host interactions to guide strategic assay design in oncology, neuroprotection, and immunology. Drawing from recent lipidomics studies and robust preclinical findings, we offer translational researchers actionable guidance for maximizing Imipramine's impact—while critically appraising the compound's limitations and future potential.

• Sumatriptan Succinate: Precision 5-HT1 Receptor Agonist for

  2026-07-06

  Sumatriptan Succinate enables high-fidelity migraine and neurovascular research through selective 5-HT1B/1D targeting and robust metabolic profiling. This guide details advanced workflows, troubleshooting, and new metabolic insights to maximize reproducibility and translational value.

• Capecitabine in Preclinical Oncology: Assay Selection and Tu

  2026-07-06

  Explore Capecitabine as a fluoropyrimidine prodrug in preclinical oncology, with a focus on assay selection, tumor microenvironment modeling, and apoptosis induction. This article offers a distinct, practical perspective for optimizing experimental design in advanced cancer research.

• Pioglitazone: PPARγ Agonist Protocols for Metabolic Research

  2026-07-05

  Pioglitazone, a selective PPARγ agonist from APExBIO, empowers researchers to model metabolic and inflammatory diseases through precise macrophage polarization and STAT pathway modulation. This guide details optimized experimental workflows, practical troubleshooting, and real-world applications that leverage literature-backed insights for robust and reproducible results.

• Nanoparticle-Mediated mRNA Delivery Reverses Trastuzumab Res

  2026-07-04

  This study presents a tumor microenvironment (TME)-responsive nanoparticle system for systemic delivery of therapeutic mRNA to overcome trastuzumab resistance in HER2-positive breast cancer. By restoring PTEN expression and suppressing PI3K/Akt signaling, this approach offers a mechanistically targeted strategy to enhance monoclonal antibody therapy efficacy.

• Dexamethasone: Glucocorticoid Anti-Inflammatory in Bench Wor

  2026-07-03

  Dexamethasone (DHAP) provides targeted, reproducible inhibition of NF-κB signaling and immune modulation for cellular and animal models. This guide translates current reference advances and bench-proven protocols into actionable steps for inflammation, neuroimmunology, and stem cell research. Discover how to maximize reliability and troubleshoot challenges with APExBIO’s trusted reagent.

• EdU Imaging Kits (Cy5): Illuminating Myogenic Differentiatio

  2026-07-03

  Explore how EdU Imaging Kits (Cy5) enable precise cell proliferation and DNA synthesis measurement in the context of mitochondrial quality control and myogenic differentiation. This article reveals unique applications and protocol insights, grounded in recent scientific advances.

• Structure-Based Discovery of NSP15 Inhibitors for SARS-CoV-2

  2026-07-02

  This article examines a study that used structure-based virtual screening to identify natural product inhibitors targeting the SARS-CoV-2 NSP15 endoribonuclease. The research highlights thymopentin and oleuropein as potent, stable inhibitors, offering new directions for antiviral drug development.

• (-)-JQ1: Precision Control for BET Bromodomain Research

  2026-07-02

  Translational researchers face increasing pressure to deliver mechanistic clarity and clinical relevance in epigenetics and cancer biology. This article explores the pivotal role of (-)-JQ1—the rigorously validated inactive JQ1 stereoisomer—in elevating experimental rigor, with a focus on the BRD4-AKT-SIRT3 axis in hyperoxia-induced lung injury. We present mechanistic insights, protocol parameters, and strategic guidance for deploying (-)-JQ1, drawing on recent studies and competitive benchmarking. By contextualizing APExBIO's (-)-JQ1 within the evolving landscape, we chart a path for next-generation translational research.

• Propidium Iodide: Strategic Guidance for Translational Cell

  2026-07-01

  This thought-leadership article examines propidium iodide's mechanistic foundations, strategic applications, and emerging frontiers in translational research. Anchored in recent advances—such as GRA12’s role in Toxoplasma gondii virulence and host cell death—it offers actionable insights for optimizing cell viability, apoptosis, and cell cycle analyses. The discussion emphasizes evidence-based protocol parameters, competitive benchmarking, and the translational impact of robust DNA intercalating dyes like APExBIO’s Propidium Iodide B7758.

• SAR131675: A Precision VEGFR-3 Inhibitor Bridging Lymphangio

  2026-07-01

  Explore SAR131675, a selective VEGFR-3 inhibitor, with an in-depth look at its mechanism, unique selectivity, and translational relevance for anti-lymphangiogenic research. This article delivers a nuanced perspective, linking preclinical findings to assay design and disease modeling.

• Haloprogin: Broad-Spectrum Antifungal Agent for Research

  2026-06-30

  Haloprogin (1,2,4-trichloro-5-((3-iodoprop-2-yn-1-yl)oxy)benzene) is a topical antimicrobial with potent antifungal and selective anti–Gram-positive activity. Its low MIC values against dermatophytes and Candida make it a valuable research tool. Clinical and animal studies confirm its efficacy in the treatment of dermatophytosis.

15162 records 1/1011 page Next 12345 下5页 Last page